3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
2
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
6
Small Cell Lung Carcinoma
4
Ovarian Neoplasms
4
Neoplasms
4
Colorectal Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Breast Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Hepatocellular
2
Urothelial Cancer
1
Urinary Bladder Diseases
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Testicular Neoplasms
1
Interventions
Fluorouracil
25
Oxaliplatin
24
Irinotecan
24
Leucovorin
23
Bevacizumab
23
Capecitabine
18
Cetuximab
15
Radiotherapy
6
Gene Expression Profiling
5
regorafenib
4
Immunohistochemistry
4
Gemcitabine
4
Folfox protocol
4
Colonoscopy
4
Cisplatin
4
Celecoxib
4
Amplified Fragment Length Polymorphism Analysis
4
Reverse Transcriptase Polymerase Chain Reaction
3
Receptor Protein-Tyrosine Kinases
3
Polymerase Chain Reaction
3
Nivolumab
3
Mitomycin
3
Doxorubicin
3
Cyclophosphamide
3
Cholecalciferol
3
Biopsy
3
Aspirin
3
sargramostim
2
pembrolizumab
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colonic Neoplasms
×
durvalumab
×
Clear all
NCT04108481
2025-03-28
iRE-C
University of Iowa
Phase 1
Terminated
5 enrolled